Skip to main content
SpringerLink
Log in

Das geht an die Nieren!

Schlechte Blutzuckereinstellung bei Diabetes mellitus

  • FORTBILDUNG_SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Die diabetesassoziierte Nephropathie (DNP) ist eine direkte Folgeerkrankung der diabetischen Stoffwechselstörung, die zu einer Angiopathie der Kapillaren des Nierenkörperchens (Glomerulum) führt. Aber nicht alle Diabetiker sind betroffen. Lesen Sie, wer besonders gefährdet ist und was Sie tun können.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 1989;4(10):859–863

    CAS  Google Scholar 

  2. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes–Langfassung, 1. Auflage. Version 2. 2013, zuletzt geändert: September 2013. Available from: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_Therapie; DOI: 10.6101/AZQ/000170.

  3. Hasslacher C et al. Nephropathie bei Diabetes. Diabetologie 2013;8:S119–S122

    Article  Google Scholar 

  4. de Zeeuw D, Akizawa T, Audhya Pet al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. The New England journal of medicine. Dec 26 2013;369(26):2492–2503.

    Article  PubMed  Google Scholar 

  5. Parving HH, Brenner BM, McMurray JJet al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. The New England journal of medicine 2012;367(23):2204–2213

    Article  CAS  PubMed  Google Scholar 

  6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England journal of medicine 2004;351(13):1296–1305

    Article  CAS  PubMed  Google Scholar 

  7. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney international 2003;63(4): 1468–1474

    Article  PubMed  Google Scholar 

  8. van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney international 2011; 79(12):1341–1352.

    Article  PubMed  Google Scholar 

  9. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of internal medicine 2001;134(8):629–636

    Article  CAS  PubMed  Google Scholar 

  10. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. CJASN 2007;2(6):1306–1316

    CAS  PubMed  Google Scholar 

  11. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of internal medicine 2013;158(11):825–830

    Article  PubMed  Google Scholar 

  12. Wada J, Makino H. Clinical Science 2013;124: 139–152

    Article  CAS  PubMed  Google Scholar 

  13. Fioretto P, Mauer M. Semin Nephrol 2007; 27(2):195–207

    Article  PubMed Central  PubMed  Google Scholar 

  14. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–1625

    Article  CAS  PubMed  Google Scholar 

  15. Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. JASN 2010;21(4):556–563.

    Article  PubMed  Google Scholar 

  16. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870–878

    Article  CAS  PubMed  Google Scholar 

  17. Drury PL, Smith GM Ferriss JB. Increased vasopressor responsiveness to aniotensin II in type 1 (insulin-dependent) diabetic patients without complications. Diabetologia 1984;27:174–179.

    CAS  PubMed  Google Scholar 

  18. Hollenberg NK, Price DA, Fisher NDet al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney international 2003;63(1):172–178

    Article  CAS  PubMed  Google Scholar 

  19. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. JASN 2005; 16(4):1135–1140

    Article  CAS  PubMed  Google Scholar 

  20. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. The Cochrane database of systematic reviews 2010(4):CD002967.

  21. Ekstrom N, Schioler L, Svensson AMet al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ open 2012;2(4)

    Google Scholar 

  22. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes care 2011; 34(6):1431–1437

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. http://www.clinicaltrials.gov.

  24. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977–986

  25. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes care 1999; 22(1):99–111

  26. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;22;365(25):2366–2376

  27. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861–869

    Article  CAS  PubMed  Google Scholar 

  28. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851–860

    Article  CAS  PubMed  Google Scholar 

  29. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15): 1547–1559

    Article  CAS  PubMed  Google Scholar 

  30. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892–1903

    Article  CAS  PubMed  Google Scholar 

  31. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of hypertension 2013;31(10):1925–1938

  32. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney international 2014

  33. Locatelli F, Barany P, Covic Aet al. Kidney Disease. Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. European Renal Association 2013;28 (6):1346–1359

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik I, Schwerpunkt Nephrologie, Universitätsklinik Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Deutschland

    Christiane Drechsler,  Andreas Schneider,  Kay-Renke Schmidt &  Christoph Wanner

Authors
  1. Christiane Drechsler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kay-Renke Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christoph Wanner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christiane Drechsler.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Prof. Dr. med. Christoph Wanner (Koautor) ist Komiteemitglied von Endpunktstudien der Firmen Boehringer-Ingelheim und Astra Zeneca. Die Autorin und übrigen Koautoren legen folgende potenzielle Interessenkonflikte offen: keine.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Drechsler, C., Schneider, A., Schmidt, KR. et al. Das geht an die Nieren!. MMW - Fortschritte der Medizin 156, 41–46 (2014). https://doi.org/10.1007/s15006-014-2867-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-014-2867-3

Keywords - The diabetic patient with nephropathy

Search

Navigation